Retour aux projets

15235.1 PFLS-LS

HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci

Résumé

HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci

Textes supplémentaires

Abstract

A new and highly innovative treatment will be realized by a novel and patentable small molecule|combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic|staphylococci. The consortium integrates a screening platform, biophysical characterization of small|molecules, medicinal chemistry, high-end characterization of mode of action and the in vivo mouse models,|to develop initial HIT compounds into preclinical candidates

Participants

Marc Gitzinger

Wirtschaftspartner

BioVersys AG Marc Gitzinger Hochbergerstrasse 60c 4057 Basel BS CH

Rainer Riedl

Kontaktperson

rainer.riedl@zhaw.ch

ZHAW Rainer Riedl Einsiedlerstrasse 31 8820 Wädenswil ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2013-07-31
Date de fin
2015-07-31
Coûts totaux approuvés
CHF 971582.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%